Published September 14, 2026
GSK announced on October 9, 2024 that it had reached settlement agreements with 10 plaintiffs' firms covering roughly 80,000 state-court Zantac cancer lawsuits — about 93% of the pending state-court cases against the company — for up to $2.2 billion. The lawsuits alleged that ranitidine, the active ingredient in the discontinued heartburn drug, degrades into NDMA, a probable human carcinogen, and that GSK failed to adequately warn users. GSK separately agreed in principle to pay $70 million to resolve a related whistleblower complaint, pending Department of Justice approval.
GSK has continued to deny that Zantac causes cancer and structured the deal with no admission of liability, saying the settlements "remove significant financial uncertainty, risk and distraction." The participating plaintiffs' firms recommended their clients accept the terms, with the settlement expected to be substantially implemented through the first half of 2025.
The deal resolves state-court claims against GSK specifically — it doesn't touch cases against other ranitidine manufacturers, including Boehringer Ingelheim and Sanofi, which have continued through the courts on their own tracks. Sanofi reached its own settlement in September 2025, while Boehringer's cases remain contested; a Delaware court dismissed more than 80,000 Zantac cases against Boehringer in April 2026 over expert-testimony standards, a ruling Atumio covered separately. The federal Zantac MDL was largely dismissed back in 2022, so almost all of this litigation — GSK's settlement included — has played out in state courts rather than the federal system.
If your case was against GSK specifically, this settlement may already affect you — but if you used a different manufacturer's ranitidine, or if you haven't filed yet, this deal doesn't resolve your situation one way or the other, and each manufacturer's cases are moving on a different timeline. If you took Zantac or a generic ranitidine product and were later diagnosed with cancer, see Atumio's Zantac case page for a free eligibility review, or start your case review directly.